choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Saphris

Saphris Newsletter
  • Saphris (Asenapine) Market 2021: Size, Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast 2027 29 Jul 2021 07:14 GMT

    … Manufacturing Process Analysis of Saphris (Asenapine) 7.4 Saphris (Asenapine) Industrial Chain … Distributors List 8.3 Saphris (Asenapine) Customers 9 Saphris (Asenapine) Market Dynamics … 44203239 8187 Our Other report : Medical Drones Market 2021 - Industry …

  • Top Drugs Losing Patent Exclusivity in 2021 29 Apr 2021 06:57 GMT

    … ANDA litigation action against Hikma Pharmaceuticals (see "Amarin Pharma, Inc … tentative FDA approval. Sutent (sunitinib), is marketed by Pfizer for the treatment … proposed generic version of the drug in 2010). Saphris (asenapine) is AbbVie…

  • MSN Group gets US FDA nod for asenapine sublingual tablets 15 Dec 2020 10:33 GMT

    … , Breckenridge Pharmaceutical, has received final approval for its Abbreviated New Drug Application … , a generic for Saphris, with the US Food and Drug Administration. “These … Breckenridge Pharmaceutical for the US Market. They are indicated for the treatment

  • Alembic Pharma gets USFDA nod for bipolar disorder treatment drug 11 Dec 2020 07:27 GMT

    New Delhi: Drug firm Alembic Pharmaceuticals on Friday said it has … Asenapine Sublingual tablets, indicated for treatment of bipolar disorder. The approved … equivalent to the reference listed drug product Saphris Sublingual tablets of Allergan …

  • Schizophrenia Drugs Market By Drug Class, Treatment, Application, Geography and Forecast 2018 - 2026 20 Dec 2019 08:04 GMT

    … analyzes and forecasts the Schizophrenia Drugs market at global and regional … Pharma Inc., Allergan Plc, Otsuka Pharmaceutical Co., Ltd and Lundbeck among … ) Saphris (Asenapine) Third Generation Abilify (Aripiprazole)   Market By Treatment Injectable …

  • Bipolar medications: Everything you need to know 11 Feb 2019 11:12 GMT

    … (Seroquel) asenapine (Saphris) aripiprazole (Abilify) ziprasidone … FDA has not approved specific antidepressants for the treatment of bipolar, so doctors … Several medications from different drug classes … trial-and-error can help people find the right medication

  • Insurance Companies vs. Doctors: Coverage varies from State to State on Autism Treatments 08 Apr 2018 12:13 GMT

    … in the treatment of Autism. The name of the medicine was Geodon … (such as schizophrenia, bipolar disorder).” Saphris Side Effects: -drowsiness -dizziness -numbness … Line All over the country doctors are frustrated, the pharmacies are …

  • Schizophrenia Drugs Market Worth $7.9 Billion by 2022 | CAGR: 2.5%: Grand View Research, Inc. 08 Nov 2017 11:47 GMT

    … market share. Pipeline drugs, undergoing clinical trials intend to block … therapeutics market based on drug class and treatment:  Therapeutic Class Outlook … (Aripiprazole Lauroxil) Fanapt (Iloperidone) Saphris (Asenapine) Vraylar (Cariprazine) Third- …

  • FDA warns on mixing opioid addiction treatments, other meds 20 Sep 2017 23:05 GMT

    … of combining medication for opioid addiction with antidepressants and other drugs that also … brain activity. The FDA warns that mixing such drugs can cause difficulty … and Zanaflex and antipsychotic drugs Abilify, Invega, Saphris and others. Meanwhile, the …

  • FDA warns on mixing opioid addiction treatments, o 20 Sep 2017 20:55 GMT

    … of combining medication for opioid addiction with antidepressants and other drugs that also … brain activity. The FDA warns that mixing such drugs can cause difficulty … and Zanaflex and antipsychotic drugs Abilify, Invega, Saphris and others. Meanwhile, the …

Satisfied with the content?

Continue to create your account.